Actavia Life Sciences, Inc.
Actavia Life Sciences, Inc. (RASP) Revenue
Annual & quarterly revenue history · segment & region breakdown
RASP · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsActavia Life Sciences, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-09-30 | $0.00B | +$0.00B | — |
| 2022-09-30 | $0.00B | +$0.00B | — |
| 2021-09-30 | $0.00B | +$0.00B | — |
| 2020-09-30 | $0.00B | +$0.00B | — |
| 2019-09-30 | $0.00B | +$0.00B | — |
| 2018-09-30 | $0.00B | +$0.00B | — |
| 2017-03-31 | $0.00B | +$0.00B | — |
| 2016-06-30 | $0.00B | +$0.00B | — |
| 2015-06-30 | $0.00B | +$0.00B | — |
| 2014-06-30 | $-0.00B | -$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Actavia Life Sciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Actavia Life Sciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Actavia Life Sciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RASP revenue · 4 questionsRASP's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Actavia Life Sciences, Inc. SEC filings · GAAP · Actavia Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026